Dianthus Therapeutics Inc. Common Stock (DNTH)
Stock · NASDAQ · Health Care
$72.16as of 10/16/2026
Price chart
Active signals
DNTH Signal Track Record
How signals performed across all stocks →What DNTH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +8.4% | 66% | September 9, 2026 |
| Bollinger Band Breakout | 25 | +0.8% | 52% | July 30, 2026 |
| Bollinger Band Breakdown | 18 | +1.8% | 56% | September 17, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +0.3% | 50% | October 8, 2026 |
| Any 20-session window (baseline) | +1.6% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendri…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 92
- Website
- dianthustx.com/
Fundamentals
- 1-day range
- $72.67$77.55
- Market cap
- $6.15B
- P/E (trailing)
- —
- P/E (forward)
- -16.16
- EPS (trailing)
- $-4.15
- Dividend yield
- —
- Beta
- 1.99
- Avg. volume
- 807.2K
How Dianthus Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Dianthus Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
- XENEXenon Pharmaceuticals Inc. Common Shares$33.49▼ 2.45%Market cap $6.24BP/E —$33.52$72.66
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
| XENE Xenon Pharmaceuticals Inc. Common Shares | $6.24B | — | $33.49 | ▼ 2.45% | $33.52$72.66 |
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Targetbenzinga · 10/15/2026
- Top 3 Health Care Stocks Which Could Rescue Your Portfolio This QuarterBenzinga · 10/6/2026
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/1/2026
- Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingYahoo · 9/29/2026
- Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?Yahoo · 9/24/2026
- Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x RunYahoo · 9/24/2026
- This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 9/11/2026
- JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135Benzinga · 9/11/2026
Insider Activity
Insider Actions →- Edward Carr · September 17, 2026 · Option Exercise20.0K @ $17.88
- Edward Carr · September 17, 2026 · Sale700 @ $104.39
- Edward Carr · September 17, 2026 · Sale1.1K @ $103.2
- Edward Carr · September 17, 2026 · Sale3.5K @ $102.39
- Edward Carr · September 17, 2026 · Sale6.8K @ $101.37
- Edward Carr · September 17, 2026 · Sale7.9K @ $100.43
- Simrat Randhawa · September 1, 2026 · Option Exercise9.4K @ $22.07
- Simrat Randhawa · September 1, 2026 · Option Exercise6.2K @ $21.77
- Simrat Randhawa · September 1, 2026 · Option Exercise7.5K @ $17.88
- Simrat Randhawa · September 1, 2026 · Sale13.3K @ $106.74
- Simrat Randhawa · September 1, 2026 · Sale7.2K @ $106.25
- Simrat Randhawa · September 1, 2026 · Sale2.6K @ $105.19
- Simon Read · August 19, 2026 · Option Exercise2.8K @ $18.36
- Simon Read · August 19, 2026 · Sale2.8K @ $117.55
- Adam M. Veness · August 13, 2026 · Option Exercise15.0K @ $18.17
Institutional Ownership
March 31, 2026
- Total shares held
- 61.85M
- Total value held
- $4.92B
- Institutional holders
- 236
- Unknown7.77M
- Unknown3.18M
- Unknown2.61M
- Unknown2.60M
- Unknown2.54M
- Unknown2.10M
- Unknown2.03M
- Unknown1.95M
- Unknown1.68M
- Unknown1.65M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants
Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.